[
    [
        {
            "time": "2018-04-01",
            "original_text": "Spark Therapeutics (ONCE) Q4 2018 Earnings Conference Call Transcript",
            "features": {
                "keywords": [
                    "earnings",
                    "conference call",
                    "Q4"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "After Hours Most Active for Feb 19, 2019: SIRI, PFE, CHK, MO, VER, FDC, ZAYO, WBA, PYPL, AGNC, ADBE, SHY",
            "features": {
                "keywords": [
                    "after hours",
                    "most active",
                    "PFE"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "diverse"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 10,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "What's in Store for Sangamo (SGMO) This Earnings Season?",
            "features": {
                "keywords": [
                    "earnings season",
                    "Sangamo"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "IWB, UNH, V, PFE: ETF Outflow Alert",
            "features": {
                "keywords": [
                    "ETF outflow",
                    "PFE"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "financials",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials",
            "features": {
                "keywords": [
                    "partnership",
                    "clinical trials",
                    "Pfizer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "Health Care Sector Update for 02/19/2019: ICPT, MDT, NEO, JNJ, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "health care sector",
                    "update"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*",
            "features": {
                "keywords": [
                    "approval",
                    "ZIRABEV",
                    "biosimilar"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster",
            "features": {
                "keywords": [
                    "cancer pill",
                    "blockbuster"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "Gliknik To Receive $15 Million Milestone Payment From Pfizer Inc. Following Clinical Progress With PF-06755347, Previously Known As GL-2045",
            "features": {
                "keywords": [
                    "milestone payment",
                    "clinical progress",
                    "PF-06755347"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "Pfizer-Lilly drug shown to help reduce back pain in late-stage trial",
            "features": {
                "keywords": [
                    "drug",
                    "back pain",
                    "trial"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "Higher dose of Pfizer-Lilly drug helps reduce back pain in study",
            "features": {
                "keywords": [
                    "higher dose",
                    "reduce back pain",
                    "study"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain",
            "features": {
                "keywords": [
                    "top-line results",
                    "Phase 3",
                    "Tanezumab"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]